ERG350 / Ergon Pharma - LARVOL DELTA

Drugging of ACOD1 is associated with tumor regression in syngeneic tumor models (AACR 2025) - "To explore the druggability of ACOD1, we synthesized a series of small MW inhibitors and selected two compounds (ERG344 and its derivative ERG350) for further study. Increased probability of survival was also observed in the CT26 colon cancer model after daily administration of ERG350 in doses ranging from 0.25 to 3 mpk. The study further reports the effect of ACOD1 inhibition in additional syngeneic models including models of hepatocellular carcinomas"

IO biomarker • Preclinical • Colon Cancer • Colorectal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor • CX3CR1 • ITGAM • MRC1